Duchossois To Sell Chamberlain Group To Blackstone - Quick Facts

Duchossois Group agreed to sell Chamberlain Group LLC to private equity funds managed by Blackstone. The transaction values Chamberlain Group at about $5 billion.

Following the close of the transaction, Chamberlain Group would remain a privately held company headquartered in Oak Brook, Ill.

As part of the deal, Duchossois Group will retain meaningful ownership in Chamberlain Group and two seats on Chamberlain Group's Board of Directors following the close of the transaction.

The transaction is expected to close by the end of 2021, subject to regulatory approvals and customary closing conditions.

Blackstone is expected to provide additional resources and expertise for Chamberlain Group to scale its software-based and connected services business into new markets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT